December 11-13, 2018



Harness the Benefits of TIL and CTL Therapies to Enhance the Efficacy of Adoptive Cell Therapy in Solid Tumors

Do you work in the drug development of TIL and/or CTL therapy?

Is networking with this expert community important to identify yourself as a key thought leader, build relationships with KOLs and discuss potential collaborations?

Would you benefit from learning about the current clinical landscape and innovative strategies to enhance the efficacy of TIL and CTL therapies?

Don’t miss your chance to network, interact and learn at the only dedicated meeting focused on optimizing the clinical translation of TIL and CTL therapies in solid tumors. Take away actionable insights to improve that will improve the manufacturing and trial design of your adoptive immunotherapy pipeline.

Join this meeting to gain unrivaled access to clinical case studies and exclusive insights into strategies to create a specific, enhanced, tumor-reactive adoptive cell therapy. Download the brochure now